Redcare Pharmacy (0RJT) Share Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0RJT Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Redcare

Pharmacy

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0RJT Stock 12 Month Forecast

Average Price Target

€117.57

▲(137.90% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Redcare Pharmacy in the last 3 months. The average price target is €117.57 with a high forecast of €165.00 and a low forecast of €74.00. The average price target represents a 137.90% change from the last price of €49.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"€57","166":"€166","84.25":"€84.3","111.5":"€111.5","138.75":"€138.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.57142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€117.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€74.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,84.25,111.5,138.75,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.325,66.53076923076924,74.73653846153846,82.9423076923077,91.14807692307693,99.35384615384616,107.5596153846154,115.76538461538462,123.97115384615385,132.1769230769231,140.3826923076923,148.58846153846156,156.79423076923078,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.325,62.88241758241759,67.43983516483516,71.99725274725274,76.55467032967033,81.11208791208792,85.6695054945055,90.22692307692307,94.78434065934066,99.34175824175824,103.89917582417581,108.4565934065934,113.01401098901098,{"y":117.57142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.325,59.53076923076923,60.736538461538466,61.94230769230769,63.14807692307693,64.35384615384615,65.55961538461538,66.76538461538462,67.97115384615384,69.17692307692307,70.38269230769231,71.58846153846153,72.79423076923077,{"y":74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":116.364,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.346,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.691,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.394,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.559,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.703,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.074,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.071,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.478,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.523,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.325,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€165.00

Average Price Target€117.57

Lowest Price Target€74.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jan Koch

Deutsche Bank

€200→€99

Buy

100.32%

Upside

Reiterated

03/05/26

Redcare Pharmacy (0RJT) Receives a Buy from Deutsche Bank

Sarah Roberts

Barclays

€110

Buy

122.58%

Upside

Reiterated

03/04/26

Barclays Sticks to Its Buy Rating for Redcare Pharmacy (0RJT)

Olivier Calvet

UBS

€74

Hold

49.74%

Upside

Reiterated

03/04/26

UBS Reaffirms Their Hold Rating on Redcare Pharmacy (0RJT)

Martin Comtesse

Jefferies

€150

Buy

203.52%

Upside

Reiterated

03/04/26

Buy Rating Maintained as Strong Prescription Growth and Long-Term Margin Ambition Outweigh Near-Term Profitability Pressure

Volker Bosse

Baader Bank

€125

Buy

152.93%

Upside

Reiterated

03/04/26

Baader Bank Reaffirms Their Buy Rating on Redcare Pharmacy (0RJT)

Gerhard Orgonas

Berenberg Bank

€165

Buy

233.87%

Upside

Reiterated

01/22/26

Berenberg Bank Keeps Their Buy Rating on Redcare Pharmacy (0RJT)

Sven Sauer

Kepler Capital

€144→€100

Buy

102.35%

Upside

Reiterated

01/07/26

Kepler Capital Remains a Buy on Redcare Pharmacy (0RJT)

Christian Salis

Hauck & Aufhaeuser

€175→€170

Buy

243.99%

Upside

Reiterated

05/07/25

Hauck & Aufhaeuser Sticks to Their Buy Rating for Redcare Pharmacy (0RJT)

Yannik Siering

Stifel Nicolaus

€190

Buy

284.46%

Upside

Reiterated

04/04/25

Strong Customer Growth and Margin Improvement Justify Buy Rating for Redcare Pharmacy

Aisyah Noor

Morgan Stanley

€140→€147

Hold

197.45%

Upside

Reiterated

03/12/25

Redcare Pharmacy NV (RDC:GR) PT Raised to EUR147 at Morgan StanleyMorgan Stanley analyst Aisyah Noor raised the price target on Redcare Pharmacy NV (RDC:GR) to EUR147.00 (from EUR140.00) while maintaining a Equalweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jan Koch

Deutsche Bank

€200→€99

Buy

100.32%

Upside

Reiterated

03/05/26

Redcare Pharmacy (0RJT) Receives a Buy from Deutsche Bank

Sarah Roberts

Barclays

€110

Buy

122.58%

Upside

Reiterated

03/04/26

Barclays Sticks to Its Buy Rating for Redcare Pharmacy (0RJT)

Olivier Calvet

UBS

€74

Hold

49.74%

Upside

Reiterated

03/04/26

UBS Reaffirms Their Hold Rating on Redcare Pharmacy (0RJT)

Martin Comtesse

Jefferies

€150

Buy

203.52%

Upside

Reiterated

03/04/26

Buy Rating Maintained as Strong Prescription Growth and Long-Term Margin Ambition Outweigh Near-Term Profitability Pressure

Volker Bosse

Baader Bank

€125

Buy

152.93%

Upside

Reiterated

03/04/26

Baader Bank Reaffirms Their Buy Rating on Redcare Pharmacy (0RJT)

Gerhard Orgonas

Berenberg Bank

€165

Buy

233.87%

Upside

Reiterated

01/22/26

Berenberg Bank Keeps Their Buy Rating on Redcare Pharmacy (0RJT)

Sven Sauer

Kepler Capital

€144→€100

Buy

102.35%

Upside

Reiterated

01/07/26

Kepler Capital Remains a Buy on Redcare Pharmacy (0RJT)

Christian Salis

Hauck & Aufhaeuser

€175→€170

Buy

243.99%

Upside

Reiterated

05/07/25

Hauck & Aufhaeuser Sticks to Their Buy Rating for Redcare Pharmacy (0RJT)

Yannik Siering

Stifel Nicolaus

€190

Buy

284.46%

Upside

Reiterated

04/04/25

Strong Customer Growth and Margin Improvement Justify Buy Rating for Redcare Pharmacy

Aisyah Noor

Morgan Stanley

€140→€147

Hold

197.45%

Upside

Reiterated

03/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Redcare Pharmacy

3 Months

xxx

Success Rate

23/32 ratings generated profit

Average Return

+20.44%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.88% of your transactions generating a profit, with an average return of +20.44% per trade.

1 Year

Christian SalisHauck & Aufhaeuser

Success Rate

21/32 ratings generated profit

Average Return

+55.33%

a rating ―

Copying Christian Salis's trades and holding each position for 1 Year would result in 65.63% of your transactions generating a profit, with an average return of +55.33% per trade.

2 Years

xxx

Success Rate

16/32 ratings generated profit

Average Return

+55.71%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +55.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RJT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0RJT has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0RJT average Analyst price target in the past 3 months is 117.57.

Each month's total comprises the sum of three months' worth of ratings.

0RJT Financial Forecast

0RJT Earnings Forecast

The previous quarter’s earnings for 0RJT were -€1.44.

0RJT Sales Forecast

Next quarter’s sales forecast for 0RJT is €833.00M with a range of €833.00M to €833.00M. The previous quarter’s sales results were €795.19M. 0RJT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0RJT has Performed in-line its overall industry.

0RJT Stock Forecast FAQ

What is GB:0RJT’s average 12-month price target, according to analysts?

Based on analyst ratings, Redcare Pharmacy’s 12-month average price target is 117.57.

What is GB:0RJT’s upside potential, based on the analysts’ average price target?

Redcare Pharmacy has 137.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Redcare Pharmacy a Buy, Sell or Hold?

Redcare Pharmacy has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Redcare Pharmacy’s share price target?

The average share price target for Redcare Pharmacy is 117.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €165.00 ,and the lowest forecast is €74.00. The average share price target represents 137.90% Increase from the current price of €49.42.

What do analysts say about Redcare Pharmacy?

Redcare Pharmacy’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Redcare Pharmacy?

To buy shares of GB:0RJT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Redcare Pharmacy (0RJT) Share Forecast & Price Target

0RJT Analyst Ratings

0RJT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Redcare Pharmacy

0RJT Analyst Recommendation Trends

0RJT Financial Forecast

0RJT Earnings Forecast

0RJT Sales Forecast

0RJT Stock Forecast FAQ

Detailed List of Analyst Forecasts